PRI’s Center for Addiction Research (CAR) is currently conducting a research study looking at improving outcomes with buprenorphine-assisted detoxification from prescription pain relievers like Dilaudid, hydrocodone, oxycodone and methadone. The study, funded by the National Institute on Drug Abuse, initially involves the use of the drug buprenorphine, which is used to taper participants off prescription pain relievers, and gabapentin, known clinically as Neurontin. After being tapered off buprenorphine, participants receive Vivitrol, an FDA-approved drug shown to help prevent relapse in individuals who stop heroin or prescription pain reliever use.
There is no cost to participate in this study, and research subjects who are found eligible will receive monetary compensation for their time. Up to 200 individuals who have difficulty stopping their use of prescription pain relievers are needed for the study. Participants should be between the ages of 18 and 65 and available to attend a clinic six days a week for 30 to 60 minutes each day during the first three weeks of their involvement. Participants will need to submit a urine sample that is negative for benzodiazepines and barbiturates prior to starting the study.
Study participants will meet with a research therapist weekly for an hour-long session that will include education and support, medication management, techniques to enhance motivation for abstinence and review of problem areas.
The study will take place in CAR’s offices on the fourth floor of PRI. The principal investigators are Alison Oliveto, Ph.D., and Michael Mancino, M.D.
Strict confidentiality for all participants is assured throughout the study. For more information, call (501) 526-7969.